1
|
Trubin P, Azar MM, Kotton CN. The respiratory syncytial virus vaccines are here: Implications for solid organ transplantation. Am J Transplant 2024; 24:897-904. [PMID: 38341028 DOI: 10.1016/j.ajt.2024.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Revised: 01/20/2024] [Accepted: 02/02/2024] [Indexed: 02/12/2024]
Abstract
In 2023, the Food and Drug Administration approved 2 recombinant subunit respiratory syncytial virus (RSV) vaccines based on prefusion RSV F glycoproteins for the prevention of RSV-associated lower respiratory tract disease. These vaccines were subsequently recommended for individuals ≥60 years of age using shared clinical decision-making by the Center for Disease Control and Prevention's Advisory Committee on Immunization Practices. The development, deployment, and uptake of respiratory virus vaccines are of particular importance for solid organ recipients who are at higher risk of infectious complications and poor clinical outcomes, including from RSV-associated lower respiratory tract disease, compared to patients without immunocompromise. This review aims to summarize what is currently known about the burden of RSV disease in solid organ transplantation, to describe the currently available tools to mitigate the risk, and to highlight considerations regarding the implementation of these vaccines before and after transplantation. We also explore areas of unmet need for organ transplant recipients including questions of RSV vaccine effectiveness and safety, inequities in disease and vaccine access based on race and socioeconomic status, and expansion of coverage to immunocompromised individuals below the age of 60 years.
Collapse
Affiliation(s)
- Paul Trubin
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA
| | - Marwan M Azar
- Department of Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, Connecticut, USA; Department of Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
| | - Camille N Kotton
- Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
2
|
Ceccarelli A, Tamarri F, Angelini R, Bakken E, Concari I, Giannoccaro E, Domeniconi G, Morri M, Reali C, Righi F, Serra S, Semprini G, Silvestrini G, Turri V, Gori D, Montalti M. Herpes Zoster Vaccine Uptake and Active Campaign Impact, a Multicenter Retrospective Study in Italy. Vaccines (Basel) 2024; 12:51. [PMID: 38250864 PMCID: PMC10818709 DOI: 10.3390/vaccines12010051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Revised: 12/29/2023] [Accepted: 01/01/2024] [Indexed: 01/23/2024] Open
Abstract
The Herpes Zoster (HZ) vaccination has proven both safe and effective in alleviating conditions related to HZ, leading to significant cost savings in national healthcare and social systems. In Italy, it is recommended and provided free of charge to individuals aged 65 and older. To achieve broad vaccination coverage, alongside ordinary immunization campaigns, active and catch-up campaigns were implemented. This retrospective observational study aimed to observe the vaccination coverage achieved in the Romagna Local Health Authority (LHA) during the 2023 active campaign, with a secondary goal of assessing the impact of the 2022 catch-up campaign and the 2023 active campaign compared to ordinary campaigns. As of 3 July 2023, an overall vaccine uptake of 13.5% was achieved among individuals born in 1958, with variations among the four LHA centers ranging from 10.2% to 17.7%. Catch-up and active campaigns together contributed to nearly half of the achieved coverage in Center No. 1 and a quarter in Center No. 2. Notably, individuals born in 1957, not included in the Center No. 2 catch-up campaign, reached significantly lower vaccination coverage compared to other cohorts and centers. Analyzing the use of text messages for active campaigns, it was observed that cohort groups did not show substantial differences in text-message utilization for warnings. However, having relatives who had experienced HZ-related symptoms significantly reduced the reliance on text messages as warnings. These results highlighted how catch-up and active campaigns effectively increased vaccine coverage. Nevertheless, differences in uptake among different centers within the same LHA and the limited contribution of other information sources compared to text messages suggest the necessity of designing campaigns involving all available channels and stakeholders to maximize vaccine uptake.
Collapse
Affiliation(s)
- Andrea Ceccarelli
- Operative Unit of Hygiene and Public Health-Forlì and Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy (G.D.)
- Unit of Hygiene and Medical Statistics, Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy
| | - Federica Tamarri
- Operative Unit of Hygiene and Public Health-Forlì and Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy (G.D.)
| | - Raffaella Angelini
- Operative Unit of Hygiene and Public Health-Ravenna, Department of Public Health, Romagna Local Health Authority, 48121 Ravenna, Italy
| | - Elizabeth Bakken
- Operative Unit of Hygiene and Public Health-Rimini, Department of Public Health, Romagna Local Health Authority, 47924 Rimini, Italy
| | - Ilaria Concari
- Operative Unit of Hygiene and Public Health-Rimini, Department of Public Health, Romagna Local Health Authority, 47924 Rimini, Italy
| | - Elsa Giannoccaro
- Operative Unit of Hygiene and Public Health-Rimini, Department of Public Health, Romagna Local Health Authority, 47924 Rimini, Italy
| | - Giada Domeniconi
- Operative Unit of Hygiene and Public Health-Forlì and Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy (G.D.)
| | - Michela Morri
- Operative Unit of Hygiene and Public Health-Rimini, Department of Public Health, Romagna Local Health Authority, 47924 Rimini, Italy
| | - Chiara Reali
- Operative Unit of Hygiene and Public Health-Forlì and Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy (G.D.)
| | - Francesca Righi
- Operative Unit of Hygiene and Public Health-Forlì and Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy (G.D.)
| | - Silvia Serra
- Operative Unit of Hygiene and Public Health-Ravenna, Department of Public Health, Romagna Local Health Authority, 48121 Ravenna, Italy
| | - Gianmaria Semprini
- Operative Unit of Hygiene and Public Health-Rimini, Department of Public Health, Romagna Local Health Authority, 47924 Rimini, Italy
| | - Giulia Silvestrini
- Operative Unit of Hygiene and Public Health-Ravenna, Department of Public Health, Romagna Local Health Authority, 48121 Ravenna, Italy
| | - Valentina Turri
- Operative Unit of Hygiene and Public Health-Ravenna, Department of Public Health, Romagna Local Health Authority, 48121 Ravenna, Italy
| | - Davide Gori
- Unit of Hygiene and Medical Statistics, Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy
| | - Marco Montalti
- Operative Unit of Hygiene and Public Health-Forlì and Cesena, Department of Public Health, Romagna Local Health Authority, 47522 Cesena, Italy (G.D.)
- Unit of Hygiene and Medical Statistics, Department of Biomedical and Neuromotor Sciences, University of Bologna, 40126 Bologna, Italy
| |
Collapse
|
3
|
Bahakel H, Feldman AG, Danziger-Isakov L. Immunization of Solid Organ Transplant Candidates and Recipients: A 2022 Update. Infect Dis Clin North Am 2023:S0891-5520(23)00025-9. [PMID: 37142511 DOI: 10.1016/j.idc.2023.03.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
Immunizations are a relatively safe and cost-effective intervention to prevent morbidity and mortality associated with vaccine preventable infection (VPIs). As such, immunizations are a critical part of the care of pre and posttransplant patients and should be prioritized. New tools are needed to continue to disseminate and implement the most up-to-date vaccine recommendations for the SOT population. These tools will help both primary care providers and multi-disciplinary transplant team members taking care of transplant patients to stay abreast of evidence-based best practices regarding the immunization of the SOT patient.
Collapse
Affiliation(s)
- Hannah Bahakel
- Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA
| | - Amy G Feldman
- Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, University of Colorado School of Medicine and Children's Hospital Colorado, 13123 East 16th Avenue, Aurora, CO 80045, USA
| | - Lara Danziger-Isakov
- Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229-3026, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
| |
Collapse
|
4
|
Adherence to Herpes Zoster (Shingles) Catch-Up Campaign at the Romagna Local Health Authority (Italy), a Multi-Center Retrospective Observational Study. Vaccines (Basel) 2022; 10:vaccines10101770. [PMID: 36298636 PMCID: PMC9611813 DOI: 10.3390/vaccines10101770] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Revised: 10/16/2022] [Accepted: 10/20/2022] [Indexed: 11/05/2022] Open
Abstract
Herpes Zoster (shingles) is an infection that occurs when varicella-zoster virus reactivates from the latent state. Incidence and severity of Herpes Zoster disease increase with age. Antiviral drugs are the elective treatment; however, prevention of disease reactivation through effective and safe vaccines is available in Italy out-of-pocket from age 65 onwards. The Romagna Local Health Authority (northern Italy) administered catch-up vaccinations in March–May 2022 for immunizations not performed during the COVID-19 pandemic. In this study, adherence rates to the catch-up campaign and recall activities adopted in two centers were investigated. The uptakes for only the catch-up vaccinations were 11.4% and 12.4%. Having suffered from Herpes Zoster or having family members who suffered from it would not seem to be drivers of increased uptake. Although sending text-messages to all involved patients was the main motivation for vaccine uptake (85.7–95.1%), word of mouth and web/news advertising also contributed to adoption in Center No. 2. In both centers, the need for greater synergy between public health departments and general practitioners to engage their patients emerged, as did the need for additional recall measures. Studying the main drivers of vaccine hesitancy, especially at the local level, can help in targeting campaigns and catch-up activities in order to achieve widespread acceptance.
Collapse
|
5
|
Neofytos D, Papanicolaou GA. Editorial: Friends and foes: "The quarrels of friends are the opportunities of foes". Curr Opin Infect Dis 2022; 35:269-270. [PMID: 35849515 DOI: 10.1097/qco.0000000000000850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- Dionysios Neofytos
- Infectious Disease Service, Geneva University Hospital, Geneva, Switzerland
| | - Genovefa A Papanicolaou
- Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
| |
Collapse
|